
Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) – Analysts at HC Wainwright reduced their FY2026 EPS estimates for Tango Therapeutics in a research report issued to clients and investors on Tuesday, November 10th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($1.50) per share for the year, down from their previous forecast of ($1.34). HC Wainwright currently has a “Buy” rating and a $67.00 price objective on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.44) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.75) EPS.
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04).
Check Out Our Latest Report on TNGX
Tango Therapeutics Trading Up 2.6%
Shares of TNGX opened at $25.50 on Thursday. Tango Therapeutics has a 52 week low of $7.60 and a 52 week high of $34.39. The firm’s 50-day simple moving average is $23.53 and its 200 day simple moving average is $22.79.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. TRV GP IV LLC bought a new stake in shares of Tango Therapeutics during the 2nd quarter valued at $120,181,383,000. Tidal Investments LLC bought a new position in shares of Tango Therapeutics in the second quarter worth $1,731,000. Handelsbanken Fonder AB bought a new position in shares of Tango Therapeutics in the second quarter worth $9,000,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Tango Therapeutics in the second quarter worth $19,884,000. Finally, Tema ETFs LLC acquired a new position in Tango Therapeutics in the second quarter valued at about $1,731,000. 78.99% of the stock is owned by institutional investors.
Insider Activity
In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of Tango Therapeutics stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $24.47, for a total value of $660,690.00. Following the completion of the sale, the insider owned 115,743 shares in the company, valued at $2,832,231.21. The trade was a 18.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jessica Newcomb sold 8,200 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total transaction of $198,604.00. Following the completion of the sale, the insider directly owned 59,121 shares of the company’s stock, valued at $1,431,910.62. This represents a 12.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 52,231 shares of company stock worth $1,254,029 over the last 90 days. 6.50% of the stock is currently owned by corporate insiders.
Key Tango Therapeutics News
Investors following TNGX have been watching these news items:
- Positive Sentiment: Canaccord Genuity reaffirmed its Buy rating, while HC Wainwright also maintained a Buy rating and a $67 price target despite revising its forecasts. Continued Buy ratings may help offset concerns about near-term losses. Canaccord Genuity sticks to its Buy rating HC Wainwright lowers expectations
- Neutral Sentiment: Shares moved above their 50-day moving average despite the earnings miss, a technical signal that may indicate improving near-term momentum. TNGX moves above its 50-day moving average
- Negative Sentiment: Tango reported a quarterly loss of $0.39 per share, wider than the $0.35 loss analysts expected, underscoring continued operating losses.
Tango Therapeutics Company Profile
Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.
Featured Articles
- Five stocks we like better than Tango Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
